FPF
CRBP icon

FNY Partners Fund’s Corbus Pharmaceuticals CRBP Stock Holding History

FNY Partners Fund’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-133
Closed -$26.1K – 673
2017
Q1 		$33K Buy
133
+66
+99% +$16.2K ﹤0.01% 831
2016
Q4 		$17K Buy
+67
New +$15.4K ﹤0.01% 387

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

FNY Partners Fund's CRBP Position: Q2 2017 in Review

FNY Partners Fund sold out of Corbus Pharmaceuticals (CRBP) in Q2 2017, closing a stake of 133 shares — an estimated $26.1K sold.

FNY Partners Fund first reported a position in CRBP in Q4 2016 and held it in 2 quarters. The position peaked at $33K in Q1 2017. 69 funds tracked by Wall St. Rank hold CRBP as of Q2 2017.

  • FNY Partners Fund reported no remaining Corbus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • FNY Partners Fund sold 133 Corbus Pharmaceuticals shares in Q2 2017, an estimated $26.1K.
  • FNY Partners Fund first reported a position in Corbus Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • FNY Partners Fund's Corbus Pharmaceuticals position peaked at $33K in Q1 2017.
  • 69 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.